BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BFB759 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BFB759\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07105488-1310@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:BFB759: Phase 2 readout est. (NCT07105488)
DESCRIPTION:BFB759\, phase 2\, Atopic Dermatitis.\nStudy: A Study Evaluatin
 g BFB759 in Moderate to Severe Atopic Dermatitis\nEstimated primary comple
 tion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bfb759#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07105488
URL:https://assetmemo.bio/drug/bfb759#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287644-1310@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:BFB759: Phase 2/3 readout est. (NCT07287644)
DESCRIPTION:BFB759\, phase 2/3\, Hidradenitis Suppurativa.\nStudy: A Study 
 Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa\nEstimate
 d primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bfb759#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07287644
URL:https://assetmemo.bio/drug/bfb759#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
